Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 4/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 12/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 10/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 6/20 | 0.42 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926894 | 0.97 | ITGA4 (0.46) | PTPN11ITGA4ITGB1ITGB3ITGA2B | |
| SCHEMBL3991617 | 0.95 | ITGA4 (0.48) | PTPN11ITGA4ITGB1ITGB3ITGA2B | |
| SCHEMBL5927441 | 0.94 | ITGA4 (0.45) | ITGA4ITGB1ITGB7KIFC1 | |
| SCHEMBL4829606 | 0.93 | ITGA4 (0.44) | PTPN11ITGA4ITGB1ITGB3ITGA2B | |
| SCHEMBL4829602 | 0.93 | ITGA4 (0.44) | PTPN11ITGA4ITGB1ITGB3ITGA2B | |
| SCHEMBL4831640 | 0.93 | KIFC1 (0.48) | PTPN11ITGA4ITGB1ITGB3ITGA2B | |
| SCHEMBL3995232 | 0.93 | ITGA4 (0.43) | PTPN11ITGA4ITGB1ITGB3ITGA2B | |
| SCHEMBL3999740 | 0.93 | KIFC1 (0.48) | PTPN11ITGA4ITGB1ITGB3ITGA2B | |
| SCHEMBL8337866 | 0.92 | PTPN11 (0.44) | PTPN11ITGA4ITGB1ITGB3ITGA2B | |
| SCHEMBL5926496 | 0.92 | ITGB3 (0.44) | ITGA4ITGB1ITGB3ITGA2BITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014533-A2 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | PTPN11 2131/4885ITGA4 312/4885ITGB1 240/4885 |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F3, F2 | PTPN11 1025/4885ITGA4 1170/4885ITGB1 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.